Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The proprotein convertase subtilisin/kexin-type 9 (PCSK9) binds to low-density lipoprotein receptors (LDLR), thereby trafficking them to lysosomes upon endocytosis and enhancing intracellular degradation to prevent their recycling. As a result, the levels of circulating LDL cholesterol (LDL-C) increase, which is a prominent risk factor for developing atherosclerotic cardiovascular diseases (ASCVD). Thus, PCSK9 has become a promising therapeutic target that offers a fertile testing ground for new drug modalities to regulate plasma LDL-C levels to prevent ASCVD. In this review, we have discussed the role of PCSK9 in lipid metabolism and briefly summarized the current clinical status of modalities targeting PCSK9. In particular, a detailed overview of peptide-based PCSK9 inhibitors is presented, which emphasizes their structural features and design, therapeutic effects on patients, and preclinical cardiovascular disease (CVD) models, along with PCSK9 modulation mechanisms. As a promising alternative to monoclonal antibodies (mAbs) for managing LDL-C, anti-PCSK9 peptides are emerging as a prospective next generation therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Mechanisms of plaque formation and rupture
Bentzon, J. F., Otsuka, F., Virmani, R., & Falk, E. (2014) · Circulation Research · doi:10.1161/circresaha.114.302721 · Cited by 2,391
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Therapeutic peptides: Historical perspectives, current development trends, and future directions
Lau, J. L., & Dunn, M. K. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.06.052 · Cited by 1,879
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1912387 · Cited by 1,665
Tabas, I., Williams, K. J., & Borén, J. (2007) · Circulation · doi:10.1161/circulationaha.106.676890 · Cited by 1,399
Cohen, J., Pertsemlidis, A., Kotowski, I. K., Graham, R., Garcia, C. K., & Hobbs, H. H. (2005) · Nature Genetics · doi:10.1038/ng1509 · Cited by 1,381
Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities
Bäck, M., Yurdagul, A., Tabas, I., Öörni, K., & Kovanen, P. T. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0169-2 · Cited by 1,341
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Subtilases: the superfamily of subtilisin-like serine proteases.
Siezen, R. J., & Leunissen, J. A. M. (1997) · Protein Science · doi:10.1002/pro.5560060301 · Cited by 896
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Raal, F. J., Kallend, D., Ray, K. K., Turner, T., Koenig, W., Wright, R. S., Wijngaard, P. L. J., Curcio, D., Jaros, M. J., Leiter, L. A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913805 · Cited by 818
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
Musunuru, K., Chadwick, A. C., Mizoguchi, T., Garcia, S. P., DeNizio, J. E., Reiss, C. W., Wang, K., Iyer, S., Dutta, C., Clendaniel, V., et al. (2021) · Nature · doi:10.1038/s41586-021-03534-y · Cited by 793
Zhang, D.-W., Lagace, T. A., Garuti, R., Zhao, Z., McDonald, M., Horton, J. D., Cohen, J. C., & Hobbs, H. H. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702027200 · Cited by 788
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis
Drechsler, M., Megens, R. T. A., van Zandvoort, M., Weber, C., & Soehnlein, O. (2010) · Circulation · doi:10.1161/circulationaha.110.961714 · Cited by 698
Borén, J., & Williams, K. J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000330 · Cited by 524
Permanent Alteration of PCSK9 With In Vivo CRISPR-Cas9 Genome Editing
Ding, Q., Strong, A., Patel, K. M., Ng, S.-L., Gosis, B. S., Regan, S. N., Cowan, C. A., Rader, D. J., & Musunuru, K. (2014) · Circulation Research · doi:10.1161/circresaha.115.304351 · Cited by 522
Kim, J., Castellano, J. M., Jiang, H., Basak, J. M., Parsadanian, M., Pham, V., Mason, S. M., Paul, S. M., & Holtzman, D. M. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.013 · Cited by 308
PCSK9 inhibitors: A new era of lipid lowering therapy
Chaudhary, R., Garg, J., Shah, N., & Sumner, A. (2017) · World Journal of Cardiology · doi:10.4330/wjc.v9.i2.76 · Cited by 299
The Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Piper, D. E., Jackson, S., Liu, Q., Romanow, W. G., Shetterly, S., Thibault, S. T., Shan, B., & Walker, N. P. C. (2007) · Structure · doi:10.1016/j.str.2007.04.004 · Cited by 251
In utero CRISPR-mediated therapeutic editing of metabolic genes
Rossidis, A. C., Stratigis, J. D., Chadwick, A. C., Hartman, H. A., Ahn, N. J., Li, H., Singh, K., Coons, B. E., Li, L., Lv, W., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0184-6 · Cited by 216
Kosenko, T., Golder, M., Leblond, G., Weng, W., & Lagace, T. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421370 · Cited by 181
PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
Shan, L., Pang, L., Zhang, R., Murgolo, N. J., Lan, H., & Hedrick, J. A. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.106 · Cited by 180
PCSK9 regulates expression of scavenger receptors and ox-LDL uptake in macrophages
Ding, Z., Liu, S., Wang, X., Theus, S., Deng, X., Fan, Y., Zhou, S., & Mehta, J. L. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy079 · Cited by 147
Jonas, M. C., Costantini, C., & Puglielli, L. (2008) · The EMBO Reports · doi:10.1038/embor.2008.132 · Cited by 119
Rousselet, E., Marcinkiewicz, J., Kriz, J., Zhou, A., Hatten, M. E., Prat, A., & Seidah, N. G. (2011) · Journal of Lipid Research · doi:10.1194/jlr.m014118 · Cited by 107
GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR Degradation
Poirier, S., Mamarbachi, M., Chen, W.-T., Lee, A. S., & Mayer, G. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.11.006 · Cited by 86
Small molecules as inhibitors of PCSK9: Current status and future challenges
Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.011 · Cited by 85
Adorni, M. P., Ruscica, M., Ferri, N., Bernini, F., & Zimetti, F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00120 · Cited by 67
Macchi, C., Favero, C., Ceresa, A., Vigna, L., Conti, D. M., Pesatori, A. C., Racagni, G., Corsini, A., Ferri, N., Sirtori, C. R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01158-6 · Cited by 51
Wang, S.-H., Huang, Y., Yuan, Y., Xia, W.-Q., Wang, P., & Huang, R. (2014) · Lipids in Health and Disease · doi:10.1186/1476-511x-13-175 · Cited by 44
Cited by
Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside
Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01690-3 · Cited by 187
Jamadade, P., Nupur, N., Maharana, K. C., & Singh, S. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01228-0 · Cited by 11
Miao, J., Wang, J., Zhou, W., & Guo, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-46671-y · Cited by 3
“Nevertheless, clinical translation of antibody-based strategies is hindered by invasive administration routes, high cost, limited shelf life, and potential immunogenicity 15,16 .”
Metadata
- Authors
- Ahamad, S., & Bhat, S. A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2022-11-29
- Volume
- 65
- Issue
- 23
- Pages
- 15513-15539
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4311083213
- Cited by
- 52
- References
- 37
- FWCI
- 9.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.